Patents by Inventor Uh Hyun Kim

Uh Hyun Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220235343
    Abstract: The present disclosure relates to a pharmaceutical composition containing an inhibitor against the expression or activation of a novel ADP-ribosyl cyclase or a naturally occurring variant thereof as an active ingredient for preventing or treating an ADP-ribosyl cyclase-mediated disease. In addition, the present disclosure relates to a composition for diagnosis of an ADP-ribosyl cyclase-mediated disease, the composition containing an agent for measuring a gene expression level or protein level of the ADP-ribosyl cyclase or a naturally occurring variant thereof. The composition of the present disclosure has the effect of inhibiting calcium increase in kidney cells, which is attributed to angiotensin II-induced ADP-ribosyl cyclase expression or activation, and as such can be advantageously used as a therapeutic agent for an ADP-ribosyl cyclase-mediated disease, particularly a renal disease.
    Type: Application
    Filed: June 25, 2020
    Publication date: July 28, 2022
    Applicants: INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY, DNT Co., Ltd.
    Inventors: Uh-Hyun KIM, Tae-Sik NAM
  • Patent number: 11071748
    Abstract: When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 27, 2021
    Assignee: Industrial Cooperation Foundation Chonbuk National University
    Inventors: Uh Hyun Kim, Dae Ryoung Park, Kwang Hyun Park
  • Publication number: 20200046750
    Abstract: When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 13, 2020
    Inventors: Uh Hyun Kim, Dae Ryoung Park, Kwang Hyun Park
  • Publication number: 20190298745
    Abstract: The present disclosure relates to a composition for regulating prostasome secretion, comprising an intracellular calcium signaling second messenger or a regulator thereof. The techniques to promote and regulate the prostasome secretion according to the present disclosure is mainly characterized by providing techniques for regulating exosome secretion based on the signaling mechanism in prostate cells. In particular, since it can directly regulate the secretion of prostasome that imparts motility to the sperm, it can he used for the verification of sperm motility in the diagnosis or treatment of infertility and can be used for the improvement of fertility and for contraception.
    Type: Application
    Filed: January 18, 2019
    Publication date: October 3, 2019
    Inventors: Kwang Hyun Park, Yoon Wha Oh, Uh Hyun Kim, Sun Eun Choi
  • Patent number: 9180171
    Abstract: The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method for inhibiting fertilization, which can inhibit the expression or function of cyclic ADP-ribose to reduce sperm motility, thereby inhibiting fertilization.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: November 10, 2015
    Assignee: Industrial Cooperation Foundation Chonbuk National University
    Inventors: Uh-Hyun Kim, Kwang-Hyun Park, Byung-Ju Kim
  • Patent number: 8816065
    Abstract: Provided are a method of preparing a zinc oxide nanostructure electrode and a method of preparing a dye-sensitized solar cell using the same. The present invention relates to a use of nicotinic acid adenine dinucleotide phosphate or a derivative thereof for promoting the differentiation of keratinocytes into fibroblasts. The present invention provides a pharmaceutical or cosmetic use of a composition containing NAADP or a derivative thereof for regenerating and improving a skin barrier, or preventing, improving or treating stratum corneum disorders such as psoriasis or atopy, and a use for promoting the differentiation of separated keratinocytes.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: August 26, 2014
    Assignee: Damy Chemical Co., Ltd.
    Inventors: Kwang-Nyeon Kim, Jung-Min Cho, Joo-Hyun Son, Uh-Hyun Kim, Kwang-Hyun Park
  • Publication number: 20130137177
    Abstract: Provided are a method of preparing a zinc oxide nanostructure electrode and a method of preparing a dye-sensitized solar cell using the same. The present invention relates to a use of nicotinic acid adenine dinucleotide phosphate or a derivative thereof for promoting the differentiation of keratinocytes into fibroblasts. The present invention provides a pharmaceutical or cosmetic use of a composition containing NAADP or a derivative thereof for regenerating and improving a skin barrier, or preventing, improving or treating stratum corneum disorders such as psoriasis or atopy, and a use for promoting the differentiation of separated keratinocytes.
    Type: Application
    Filed: August 10, 2011
    Publication date: May 30, 2013
    Applicant: DAMY CHEMICAL CO., LTD.
    Inventors: Kwang-Nyeon Kim, Jung-Min Cho, Joo-Hyun Son, Uh-Hyun Kim, Kwang-Hyun Park
  • Patent number: 8314082
    Abstract: The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: November 20, 2012
    Assignee: Industrial Cooperation Foundation Chonbuk National University
    Inventors: Uh-Hyun Kim, Ho-Jeong Kwon, Mie-Jae Im, Seon-Young Kim, Kwang-Hyun Park, So-Young Rah, Tae-Sik Nam, Byung-Ju Kim, Gul Rukhsana
  • Publication number: 20120189607
    Abstract: The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method for inhibiting fertilization, which can inhibit the expression or function of cyclic ADP-ribose to reduce sperm motility, thereby inhibiting fertilization.
    Type: Application
    Filed: January 25, 2012
    Publication date: July 26, 2012
    Applicant: Industrial Cooperation Foundation Chonbuk National University
    Inventors: Uh-Hyun Kim, Kwang-Hyun Park, Byung-Ju Kim
  • Patent number: 8133872
    Abstract: The administration of nicotinic acid adenine dinucleotide phosphate (NAADP) or a pharmaceutically acceptable salt thereof to a host in need thereof for the treatment of type-2 diabetes has been disclosed.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: March 13, 2012
    Assignee: Industrial Cooperation Foundation, Chonbuk National University
    Inventors: Uh Hyun Kim, Kwang Hyun Park, Myung Kwan Han
  • Publication number: 20110281826
    Abstract: The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.
    Type: Application
    Filed: May 31, 2011
    Publication date: November 17, 2011
    Inventors: Uh-Hyun Kim, Ho-Jeong Kwon, Mie-Jae Im, Seon-Young Kim, Kwang-Hyun Park, So-Young Rah, Tae-Sik Nam, Byung-Ju Kim, Gul Rukhsana
  • Publication number: 20100069619
    Abstract: The present disclosure relates to bisphenyl compounds that are useful for inhibit the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.
    Type: Application
    Filed: December 28, 2007
    Publication date: March 18, 2010
    Inventors: Uh-Hyun Kim, Ho-Jeong Kwon, Mie-Jae Im, Seon-Young Kim, Kwang-Hyun Park, So-Young Rah, Tae-Sik Nam, Byung-Ju Kim, Gul Rukhsana
  • Publication number: 20090306006
    Abstract: Nicotinic acid adenine dinucleotide phosphate and a pharmaceutically acceptable derivative thereof are useful for the treatment of type-2 diabetes.
    Type: Application
    Filed: May 19, 2009
    Publication date: December 10, 2009
    Inventors: Uh Hyun Kim, Kwang Hyun Park, Myung Kwan Han
  • Publication number: 20020137779
    Abstract: The present invention provides the use of L-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes(NIDDM; non-insulin dependent diabetes mellitus). The present invention also provides the pharmaceutical composition containing the chemical L-2-oxothiazolidine-4-carboxylic acid as an active agent for the treatment of type 2 diabetes and the method for the treatment of type 2 diabetes comprising administering to a mammal having the same disease.
    Type: Application
    Filed: June 6, 2001
    Publication date: September 26, 2002
    Applicant: Advanced Biochemicals Inc.
    Inventors: Uh-Hyun Kim, Myung-Kwan Han, Young-Mi Shin, Kwang-Hyun Park, Kum-Jae Park